Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis 

In an article published in the latest edition of the Journal for Clinical Studies, IXICO’s Chief Scientific Officer Robin Wolz outlines how data from the landmark Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, can help better understand the complementary use of amyloid positron emission tomography (PET) and blood based biomarkers (BBMs) in the diagnosis of Alzheimer‘s disease (AD).

Analysis of the Bio-Hermes data validates utility of a two-stage screening process where initial BBM tests are followed by amyloid PET scans for ambiguous cases. This approach enhances trial efficiency by reducing PET screen failure rates and improving the identification of suitable candidates for clinical trials.

By examining the interplay between imaging and BBMs, the article highlights how BBMs offer a more accessible, less invasive, and cost-effective alternative where appropriate, while acknowledging the need for a gold-standard assessment from PET in certain cases.

Read the full editorial here

---